Core Insights - Eli Lilly has achieved significant success in the GLP-1 drug market, with a stock price increase of 200% over the past three years and a leadership position in the U.S. market, holding over 60% market share [1][6][10] - The obesity drug market is projected to reach nearly $100 billion by the end of the decade, indicating potential for continued growth for Eli Lilly [7] Company Performance - Eli Lilly's revenue has shown double-digit growth, with Mounjaro and Zepbound generating over $11 billion in revenue during the recent quarter, both experiencing triple-digit revenue gains [1][6] - The company's gross margin stands at 85.40%, and it has a market capitalization of $988 billion [9] Product Overview - GLP-1 drugs, including Eli Lilly's tirzepatide (Mounjaro and Zepbound), help manage blood sugar levels and appetite, contributing to their popularity [4][5] - Eli Lilly is also developing orforglipron, an oral weight loss candidate currently under regulatory review, which could further enhance its market position [5][9] Competitive Landscape - While Novo Nordisk was the first to market with GLP-1 drugs, Eli Lilly has been gaining market share and has outperformed competitors in clinical trials [6][9] - Other companies, such as Pfizer and Viking Therapeutics, are looking to enter the market, but Eli Lilly's established brand strength and product efficacy are expected to sustain its revenue growth [10]